Dong-A ST Completes Patient Enrollment for Global Phase 3 Clinical Trial of Psoriasis Treatment
[Asia Economy Reporter Minji Lee] Dong-A ST announced on the 19th that patient enrollment for the global Phase 3 clinical trial of the chronic plaque psoriasis treatment DMB-3115 has been completed. The patient enrollment countries include Poland and eight other countries.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- "Total Blockout"... Trump Team Tosses All 'Items Received from China' in Trash Before Boarding Private Jet
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
The company stated, "This is to evaluate the efficacy, safety, and immunogenicity of DMB-3115, a biosimilar of Stelara," adding, "Stelara is the original biologic drug approved for the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
